Baiyunshan subsidiary acquires Zhejiang Pharmaceutical for 500.50m yuan

On December 17, 2025, GP Corp., a subsidiary of Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd., signed an Equity Transfer Agreement to acquire 100% equity in Zhejiang Pharmaceutical Industry Company for 500.50 million yuan. Zhejiang Pharmaceutical is a distribution company in Zhejiang Province. The acquisition price is a premium over the listing floor price of 430.00 million yuan.

The transaction, classified as disclosable under Hong Kong Listing Rules, aims to utilize Zhejiang Pharmaceutical's strong customer network and annual sales exceeding 4.0 billion yuan in the Yangtze River Delta Region. This move is expected to optimize GP Corp.'s industrial layout in East China and enhance its domestic market coverage.

The valuation of the target equity as of May 31, 2025, using an asset-based approach, determined its value at 392.2339 million yuan. The board views the acquisition as aligned with its long-term development strategy, anticipating positive impacts on business expansion and shareholder value.